Markus Warmuth

H3 Biomedicine

Research Area

Biography

Markus Warmuth has not added Biography.
If you are Markus Warmuth and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 2	2015

Other Publications

Article	Year
Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood\| PubMed ID: 12393636	2003
The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate. Blood\| PubMed ID: 12393654	2003
SRC family kinases: potential targets for the treatment of human cancer and leukemia. Current pharmaceutical design\| PubMed ID: 14529415	2003
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nature genetics\| PubMed ID: 15098032	2004
An efficient rapid system for profiling the cellular activities of molecular libraries. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 16492761	2006
A general strategy for creating "inactive-conformation" abl inhibitors. Chemistry & biology\| PubMed ID: 16873026	2006
Ba/F3 cells and their use in kinase drug discovery. Current opinion in oncology\| PubMed ID: 17133113	2007
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 17185414	2007
B-Raf kinase inhibitors for cancer treatment. Current opinion in investigational drugs (London, England : 2000)\| PubMed ID: 17621874	2007
Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nature medicine\| PubMed ID: 17632527	2007
Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner. Annals of hematology\| PubMed ID: 17668209	2007
Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells. Annals of hematology\| PubMed ID: 17960378	2008
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorganic & medicinal chemistry letters\| PubMed ID: 18667312	2008
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer cell\| PubMed ID: 18772113	2008
A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. Molecular cell\| PubMed ID: 19150426	2009
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature\| PubMed ID: 20072125	2010
Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. Biochimica et biophysica acta\| PubMed ID: 20152788	2010
The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells. Cancer research\| PubMed ID: 20530672	2010
A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl. Journal of medicinal chemistry\| PubMed ID: 20604564	2010
The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. Cancer research\| PubMed ID: 20670954	2010
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Science translational medicine\| PubMed ID: 20881279	2010
Hedgehog pathway activation in chronic myeloid leukemia. Cell cycle (Georgetown, Tex.)\| PubMed ID: 20928937	2010
Allosteric inhibition of BCR-ABL. Cell cycle (Georgetown, Tex.)\| PubMed ID: 20930519	2010
Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nature medicine\| PubMed ID: 21076395	2010
Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer research\| PubMed ID: 21324920	2011
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nature genetics\| PubMed ID: 21892161	2011
Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 21949247	2011
Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL. Blood\| PubMed ID: 22130798	2012
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature\| PubMed ID: 22460905	2012
Measuring the tyrosine kinase activity: a review of biochemical and cellular assay technologies. Expert opinion on drug discovery\| PubMed ID: 23484970	2008
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin... Journal of medicinal chemistry\| PubMed ID: 23742252	2013
Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist. ACS medicinal chemistry letters\| PubMed ID: 24900187	2010
Profiling the kinome for drug discovery. Drug discovery today. Technologies\| PubMed ID: 24980528	2006
NAMPT is the cellular target of STF-31-like small-molecule probes. ACS chemical biology\| PubMed ID: 25058389	2014
Total synthesis of 6-deoxypladienolide D and Assessment of Splicing Inhibitory Activity in a Mutant SF3B1 cancer cell line. Organic letters\| PubMed ID: 25376106	2014
Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3? Splice Site Selection through Use of a Different Branch Point. Cell reports\| PubMed ID: 26565915	2015